McSAF Inside Oncology

Is developing a new generation of immunoconjugates targeting CD56+ cancers. Its first candidate is an ADC, designed to deliver a cytotoxic load directly to tumour cells, with a focus on small cell lung cancer and Merkel cell carcinoma.